trending Market Intelligence /marketintelligence/en/news-insights/trending/-qTKxI7Pw8Tv0m27SBO5BA2 content esgSubNav
In This List

GSK, Innoviva submit application in Japan for lung disease therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GSK, Innoviva submit application in Japan for lung disease therapy

GlaxoSmithKline PLCand Innoviva Inc. are seeking Japanese approval for Trelegy Ellipta, their triple drug inhaler therapy to treat a certain lung disease.

The companies filed an application asking Japan's Ministry of Health, Labour and Welfare, to approve the treatment for patients with chronic obstructive pulmonary disease.

The lung disease affects about 5 million people in Japan, said the company. "Many patients require combination treatment with different types of medicines to reduce both symptoms and exacerbations but there is currently no triple therapy available in Japan delivered in a single inhaler," Dave Allen, GSK's head of respiratory area R&D, said in a statement.

The triple inhaler therapy was approved in the EU and the U.S. last year.